Skip to main content
Erschienen in: Pituitary 5/2016

Open Access 12.07.2016

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly

verfasst von: Julie M. Silverstein

Erschienen in: Pituitary | Ausgabe 5/2016

Abstract

Purpose

Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension. Pasireotide is a new-generation, multireceptor-targeted somatostatin receptor ligand approved for CD (subcutaneous [SC] injection formulation) and acromegaly (long-acting release [LAR] formulation). In clinical studies of pasireotide, hyperglycemia-related adverse events (AEs) were frequently observed. This review highlights differences in reported rates of hyperglycemia in pasireotide trials and discusses risk factors for and management of pasireotide-associated hyperglycemia.

Methods

Clinical trials evaluating pasireotide in patients with CD or acromegaly were reviewed.

Results

The frequency of hyperglycemia-related AEs was lower in patients with acromegaly treated with pasireotide LAR (57.3–67.0 %) than in patients with CD treated with pasireotide SC (68.4–73.0 %). Fewer patients with acromegaly treated with pasireotide LAR discontinued therapy because of hyperglycemia-related AEs (Colao et al. in J Clin Endocrinol Metab 99(3):791–799, 2014, 3.4 %; Gadelha et al. in Lancet Diabetes Endocrinol 2(11):875–884, 2014, 4.0 %) than did patients with CD treated with pasireotide SC (Boscaro et al. in Pituitary 17(4):320–326, 2014, 5.3 %; Colao et al. in N Engl J Med 366(10):914–924, 2012, 6.0 %). Hyperglycemia-related AEs occurred in 40.0 % of patients with acromegaly treated with pasireotide SC, and 10.0 % discontinued treatment because of hyperglycemia. Ongoing studies evaluating pasireotide LAR in patients with CD and management of pasireotide-induced hyperglycemia in patients with CD or acromegaly (ClinicalTrials.gov identifiers NCT01374906 and NCT02060383, respectively) will address these key safety issues.

Conclusions

Disease pathophysiology, drug formulation, and physician experience potentially influence the differences in reported rates of pasireotide-induced hyperglycemia in CD and acromegaly. Hyperglycemic effects associated with pasireotide have a predictable pattern, can be managed with antidiabetic agents, and are reversible upon discontinuation.

Introduction

Cushing’s disease (CD) and acromegaly are rare diseases characterized by the increased production of adrenocorticotropic hormone (ACTH) in the former and growth hormone (GH) in the latter [1]. In CD, hypercortisolemia is caused by the secretion of ACTH from a corticotroph pituitary tumor. In acromegaly, GH excess, most commonly from a somatotroph pituitary tumor, causes downstream hypersecretion of insulin-like growth factor 1 (IGF-1). Chronic elevation of cortisol (CD) and GH and IGF-1 (acromegaly) levels is associated with increased mortality risk and worsening comorbidities in both conditions [1, 2]. Thus, in both diseases, the treatment goals include normalization of hormone levels, reversal of clinical features, prevention of disease recurrence, and reduction in tumor volume in cases of pituitary macroadenomas [1, 3].
Surgery is considered first-line treatment and provides adequate control of cortisol levels in many patients with CD (65–90 %) [4] and GH and IGF-1 levels in patients with acromegaly (microadenomas, >85 %; macroadenomas, 40–50 %) [3]. Despite the success rates associated with surgery, 5–10 % of patients with CD [4] and 2–8 % of patients with acromegaly [3] will experience disease recurrence within 5 years after achieving postoperative hormone remission. Medical therapy (sometimes used as a bridge until adjuvant radiation therapy has taken full effect) is an option for patients with recurrent or persistent CD or acromegaly following surgery.
Pasireotide is a new-generation, multireceptor-targeted somatostatin receptor ligand (SRL) approved for the treatment of patients with CD (subcutaneous [SC] formulation) [5] or acromegaly (long-acting release [LAR] formulation) [6]. It is indicated for patients who do not achieve control with surgery and/or for whom surgery is not an option [5, 6]. Pasireotide binds to several known somatostatin receptor (sst) subtypes that are expressed by corticotroph and somatotroph tumors, resulting in decreased secretion of ACTH and GH, respectively. Both corticotroph and somatotroph tumors express relatively high levels of sst2 and sst5 [7]. Compared with octreotide, pasireotide binds with higher affinity to sst1 (30-fold), sst3 (5-fold), and sst5 (39-fold) and lower affinity to sst2 (3-fold) [8, 9]. Pasireotide also binds with higher affinity than lanreotide to sst1 (19-fold), sst3 (9-fold), and sst5 (106-fold) but with lower affinity to sst2 (2-fold) [8]. The combination of the broad binding profile of pasireotide with its preferential binding to sst5 provides therapeutic rationale for its use in the treatment of CD and acromegaly. Although its efficacy in clinical studies has warranted consideration of pasireotide as the first treatment of choice among SRLs, the effect of pasireotide on glucose metabolism should be considered when choosing the best SRL option for each patient [10]. This review provides a summary of data from clinical studies and case reports that document hyperglycemia-related adverse events (AEs) associated with pasireotide in patients with either acromegaly or CD.

Clinical efficacy of pasireotide in CD and acromegaly

Pasireotide SC in CD

In a phase 3 study of 162 patients with persistent or recurrent CD or newly diagnosed disease, who were not eligible for surgery, twice-daily injections of pasireotide SC provided rapid reductions in mean levels of urinary-free cortisol (UFC) that were sustained during treatment [11]. After 12 months of pasireotide 600 and 900 µg twice daily, 13 and 25 % of patients achieved UFC levels at or below the upper limit of the normal range, respectively. At 12 months, tumor volume reductions were also observed with 600 µg (−9.1 %) and 900 µg (−43.8 %). Decreases in mean UFC were associated with improved signs and symptoms of disease, including systolic blood pressure (mean change from baseline, −6.1 mm Hg), diastolic blood pressure (mean change from baseline, −3.7 mm Hg), weight (mean change from baseline, −6.7 kg), and health-related quality-of-life score (mean change from baseline, 11.1 points). Improvements in facial rubor and supraclavicular and dorsal fat pads were also reported. In addition, 69 % of patients (n = 11) who remained in the study for 60 months achieved UFC levels at or below the upper limit of the normal range [12].

Pasireotide in acromegaly

In a phase 3 study of patients with acromegaly who were naive to medical therapy, significantly more patients achieved biochemical control (GH < 2.5 ng/mL and age- and sex-adjusted IGF-1) after 1 year of monthly injections of pasireotide LAR 40 mg than after 1 year of monthly injections of octreotide LAR 20 mg (31.3 vs 19.2 %) [13]. Tumor volume reductions were similar between the 2 treatment groups (pasireotide LAR, 40 %; octreotide LAR, 38 %), and both therapies improved symptoms of disease (e.g., perspiration, fatigue, osteoarthralgia, paresthesia, headache) and quality of life.
In another phase 3 study that enrolled patients with acromegaly who were inadequately controlled by other SRLs, monthly injections of pasireotide LAR 40 mg (15 %) and 60 mg (20 %) provided greater biochemical control than the active control treatment (octreotide LAR 30 mg or lanreotide Autogel 120 mg; 0 %) at 6 months [14]. Furthermore, more patients in the pasireotide LAR 40 and 60-mg groups achieved tumor volume reductions of >25 % than did those in the active control group (18.5 and 10.8% vs 1.5 %). Improvements in symptom severity scores also occurred at higher degrees in patients in the pasireotide LAR 40 and 60-mg groups than in those in the active control group. Symptoms included headache, fatigue, perspiration, paresthesia, and osteoarthralgia.
The efficacy and safety of pasireotide SC in acromegaly have also been investigated. In a phase 2 extension study, 33 % of patients (3 of 9) achieved biochemical control after 24 months of treatment [15]. Up to 75 % of patients who responded to treatment demonstrated tumor volume reductions of ≥20 %. Additionally, the number of patients showing improvements in symptoms of disease (i.e., headache, fatigue, perspiration, osteoarthralgia) approximately doubled during the course of the study.

Hyperglycemia associated with pasireotide in CD and acromegaly

Clinical trials experience

In clinical trials, the safety profile of pasireotide included AEs, mostly related to gastrointestinal symptoms and cholelithiasis, that were largely consistent with other SRLs [5, 6]. However, compared with other SRLs, treatment with pasireotide is associated with a higher frequency of hyperglycemia in patients with CD or acromegaly [11, 13, 14]. The reported rates of hyperglycemia-related AEs and the percentage of patients who discontinued therapy from such events differ across clinical studies of pasireotide in CD and acromegaly (Table 1). Further comparison of the rates shows that the frequency of hyperglycemia-related AEs was lower in patients with acromegaly who received pasireotide LAR (57.3–67.0 %) [13, 14] than in patients with CD who received pasireotide SC (68.4–73.0 %) [11, 16]. Interestingly, fewer patients with acromegaly who received pasireotide LAR discontinued treatment because of hyperglycemia-related AEs, as reported in 2 separate trials (3.4 and 4.0 %), [13, 14] compared with patients with CD who received pasireotide SC, also as reported in 2 separate trials (6.0 and 5.3 %) [11, 16]. In a clinical study that evaluated the efficacy and safety of pasireotide SC in acromegaly, hyperglycemia-related AEs occurred in 40.0 % of patients, and 10.0 % of patients discontinued treatment because of such events [15].
Table 1
Hyperglycemia-related AEs associated with pasireotide in clinical studies of Cushing’s disease or acromegaly
Study
Disease
Study description
Study duration
Drug formulation (dosing)
Hyperglycemia-related AEs
Discontinuations due to hyperglycemia-related AEs (%)
Colao et al. [11]
Cushing’s disease
Phase 3
12 months
Pasireotide SC (600, 900 µg b.i.d)
73.0 %
6.0
Boscaro et al. [16]
Cushing’s disease
Phase 2, extension
6 months
Pasireotide SC (600 µg b.i.d; 900 µg with suboptimal control)
68.4 %
5.3
Colao et al. [13]
Acromegaly
Phase 3
12 months
Pasireotide LAR (40 mg; dose increase to 60 mg with suboptimal control)
57.3 %
3.4
Gadelha et al. [14]
Acromegaly
Phase 3
6 months or longer
Pasireotide LAR (40, 60 mg)
40 mg, 67.0 %
60 mg, 61.0 %
4.0
Petersenn et al. [15]
Acromegaly
Phase 2, extension
6 months or longer
Pasireotide SC (200, 400, 600 µg; 900 µg with suboptimal control)
40.0 %
10.0
AE adverse event, b.i.d twice daily, LAR long-acting release, SC subcutaneous
Several underlying factors could contribute to differences in the reported frequency of pasireotide-induced hyperglycemia among patients with CD or acromegaly. In clinical studies of acromegaly, the rates of pasireotide-induced hyperglycemia-related AEs were lower than those in CD (Fig. 1a). This could be related to disease pathophysiology since the dysregulation of glucose metabolism in CD and acromegaly could be uniquely linked to downstream effects associated with chronic exposure to elevated levels of cortisol or GH/IGF-1, respectively [17, 18]. Also, because studies of pasireotide in CD occurred before those in acromegaly, the benefit of physician experience could have led to lower rates of study discontinuation in the acromegaly trials (Fig. 1b). This could be attributed to a better understanding of the mechanisms underlying pasireotide-induced hyperglycemia and its optimal management in patients with acromegaly or CD. Despite the higher frequency of hyperglycemia-related AEs associated with pasireotide than with other medical therapies for acromegaly or CD, results from other clinical studies suggest that the hyperglycemic effect associated with treatment has a predictable pattern, can be managed with antidiabetic medications (ADM), and is reversible upon discontinuation of treatment with pasireotide.

Mechanisms of pasireotide-induced hyperglycemia

It has been reported that impaired glucose metabolism observed in patients with CD or acromegaly is uniquely associated with disease pathophysiology. Chronic exposure to elevated GH and IGF-1 levels is associated with insulin resistance, which may be counteracted by the compensatory hyperfunction of pancreatic beta cells in patients with acromegaly with normal glucose tolerance [18]. Similarly, in CD, chronic hypercortisolism blocks the binding of insulin to peripheral tissues, resulting in insulin resistance, and inhibits the release of insulin by pancreatic beta cells [17]. Excess cortisol can also affect glucose metabolism in hepatic tissue by stimulating gluconeogenesis or indirectly inhibiting insulin sensitivity by depleting storage of hepatic glycogen.
Recently, there has been a greater understanding of the mechanisms that underlie the development of hyperglycemia in patients with acromegaly or CD treated with pasireotide. The hyperglycemic effects of pasireotide are primarily due to its tendency to reduce insulin and incretin secretion [19]. Insulin secretion is mediated in large part by sst2 and sst5 [20, 21], and glucagon secretion is mediated primarily by sst2 [21, 22]. Pasireotide binds to sst2 and sst5 and binds with highest affinity to sst5, which is expressed not only by pituitary cells but also by other cell types. For example, pasireotide binds to sst5 in pancreatic islet cells, which leads to reduced insulin secretion that is not observed with SRLs that bind to sst2 with greater affinity [19, 23]. Reduced insulin levels associated with pasireotide are unable to counterbalance the reduced insulin sensitivity caused by uncontrolled acromegaly or CD [18]. However, two mechanisms could explain why the hyperglycemic effect is transient. First, pasireotide has minimal effects on glucagon secretion and no effects on insulin sensitivity in healthy volunteers [19]. In contrast, octreotide and lanreotide suppress glucagon secretion, which could be due to increased binding of sst2 [21, 22], a key mediator of glucagon secretion to which octreotide and lanreotide bind with greater affinities than pasireotide [8]. By improving biochemical control, it is likely that insulin sensitivity will increase, which should improve glucose tolerance, even if insulin secretion remains reduced. Second, it was reported that levels of IGF-binding protein 2 increased after 24 weeks of pasireotide LAR [24], which could attenuate the long-term hyperglycemic effects of pasireotide LAR.

Levels of fasting plasma glucose and glycated hemoglobin during treatment course

Fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) levels are parameters used to assess glycemic control [25]. In a clinical study of patients with acromegaly, it was reported that up to 45 % of patients with baseline FPG between 100 and 126 mg/dL had FPG levels ≥126 mg/dL after 26 months of pasireotide LAR [26]. In a clinical study of patients with CD treated with pasireotide, worsened diabetic status was observed in 76 % of patients who had normal HbA1c levels at baseline [27]. During the course of treatment in patients with acromegaly or CD, mean FPG levels peaked after 1 month of pasireotide and thereafter remained stable or slightly decreased [11, 12, 14, 2628]. In some patients, levels of FPG and HbA1c were stabilized during the course of treatment with pasireotide LAR for up to 26 months [26, 27]. These observations suggest that pasireotide initially induces an increase in FPG and HbA1c levels, which then stabilize during the course of treatment.

Predictive risk factors of pasireotide-induced hyperglycemia

In CD, the prevalence of impaired glucose tolerance or diabetes mellitus at diagnosis is 21–64 % and 20–47 %, respectively [29]. Similarly, the prevalence of impaired fasting glucose and diabetes are higher in patients with acromegaly compared with the general population, predisposing patients to a greater risk of developing hyperglycemia [30]. This suggests that baseline glycemic status before the initiation of pasireotide treatment could be predictive of the extent and severity of hyperglycemia associated with treatment. In a phase 3 study of patients with acromegaly, baseline FPG > 100 mg/dL correlated with the development of higher FPG and HbA1c levels and a higher degree of hyperglycemia during pasireotide LAR treatment [24]. Moreover, it was reported that increasing the dose of pasireotide LAR from 40 to 60 mg was associated with a 21–36 % increased risk of developing hyperglycemia [31, 32]. Regarding disease control as a predictive factor, reductions in GH and IGF-1 in patients with newly diagnosed acromegaly who were treated with octreotide for 6 months without ADM were shown to correlate with change in HbA1c levels [33]; however, a similar association in patients treated with pasireotide has not yet been studied. Other predictive risk factors associated with developing hyperglycemia in patients with acromegaly treated with pasireotide LAR include body mass index ≥25 kg/m2, diabetes at baseline, and history of dyslipidemia [34]. Because certain populations are at greater risk of hyperglycemia associated with pasireotide, proactive management and monitoring of these patients are critical for improving clinical outcomes.

Management of pasireotide-induced hyperglycemia

Optimal treatment with ADMs

As previously discussed, in phase 3 studies of pasireotide SC in CD and pasireotide LAR in acromegaly, the majority of hyperglycemia-related AEs were mild to moderate in severity [11, 13, 14]. Even in patients with acromegaly with FPG > 250 mg/dL at baseline, ADM initiated within 2 weeks of the first dose of pasireotide LAR led to rapid decreases in FPG, suggesting that early treatment intervention with ADMs could optimally manage pasireotide-induced hyperglycemia [34]. Metformin has been shown to be minimally effective in reducing pasireotide-induced hyperglycemia in healthy volunteers [35]; however, this study measured effects on glucose metabolism after only 6 days, which may have been too brief to observe long-term effects of metformin. For instance, metformin has been shown to increase glucagon-like peptide 1 (GLP-1) [36], which may at least partially compensate for the reduction in GLP-1 associated with pasireotide [19]. Antidiabetic medication, primarily metformin, was administered in 38–48 % of patients in acromegaly trials [13, 14, 26]. Mean HbA1c levels in patients with acromegaly naive to medical therapy who developed pasireotide-induced hyperglycemia were <7 % after 12 months when treated with metformin alone or in combination with other ADMs [37]. A case study of a patient with CD exemplified that control of hyperglycemia could be achieved with metformin in combination with glipizide and sitagliptin [38]. These results suggest that metformin is useful for some patients in treating pasireotide-associated hyperglycemia.
In some case study reports, treatment with metformin alone was insufficient in providing glycemic control to patients with pasireotide-induced hyperglycemia [3941]. In these cases, treatment with insulin alone or glipizide with or without insulin was able to quickly reduce FPG levels. Dietary control or modification could also be important for management of pasireotide-induced hyperglycemia [16, 42]. In healthy volunteers who were administered pasireotide SC, coadministration with liraglutide, a GLP-1 agonist, was most effective in reducing serum glucose levels (72 % lower than with pasireotide alone) [35]. Coadministration with vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was most effective in attenuating the reduction in serum insulin levels (71 % higher than with pasireotide alone). These studies indicate that by following standard guidelines for the treatment of diabetes and adapting treatment with ADMs on the basis of each patient’s glycemic status, pasireotide-induced hyperglycemia can be effectively managed.

Treatment recommendations

Medical expert recommendations have been established for the management of pasireotide-induced hyperglycemia in patients with CD [17, 43]. In patients not currently treated with insulin, and particularly for those with insulin resistance, it is recommended that metformin be initiated or continued if FPG > 126 g/dL or HbA1c is >6.5 % [43]. In cases in which patients fail to achieve glycemic control with metformin, it is suggested that a DPP-4 inhibitor be added. A GLP-1 receptor agonist should replace the DPP-4 inhibitor if HbA1c remains >7.0 %. If neither DPP-4 inhibitors nor GLP-1 receptor agonists provide glucose control, it is suggested that treatment with insulin be initiated while maintaining metformin treatment. Although no specific recommendations regarding pasireotide-induced hyperglycemia in patients with acromegaly have been published, treatment with metformin plus a DPP-4 inhibitor, GLP-1 agonist, or insulin would most likely have similar efficacy.

Monitoring recommendations

Patients with CD or acromegaly who initiate, discontinue, or need dose adjustment of pasireotide should be proactively managed in accordance with current monitoring guidelines and recommendations. Levels of FPG and HbA1c should be evaluated before initiation of treatment, and blood glucose should be monitored weekly for the first 2–3 months after initiation and for the first 2–6 weeks after a dose increase [5, 6]. Similarly, medical expert opinion also recommends that, in patients with normal glucose metabolism prior to initiating pasireotide, fasting and postprandial glucose levels should be monitored several times per day, twice during the first week, and once weekly thereafter [17, 43]. Moreover, patients with abnormal glucose metabolism during treatment should be monitored daily upon initiating pasireotide and while adjusting treatment as necessary to optimally control glycemic levels [5, 6, 17, 43]. If warranted, dose reduction or discontinuation of pasireotide should be implemented if hyperglycemia is not controllable despite medical management [5, 6]. It is suggested that FPG and HbA1c levels of patients who discontinue pasireotide may need to be assessed frequently to reduce the risk of developing hypoglycemia.

Reversibility of hyperglycemia upon discontinuation of pasireotide

Clinical studies of pasireotide in healthy volunteers and in patients with CD or acromegaly suggest that the hyperglycemic effects associated with pasireotide have a predictable pattern and could be effectively managed by following recommended guidelines set forth by expert opinions [5, 6, 17, 43]. Moreover, deterioration in glycemic status associated with pasireotide is reversible upon treatment discontinuation, which potentially restores glycemic parameters to normoglycemic levels [44]. The reversibility of the hyperglycemic effects of pasireotide has been shown in a pharmacokinetic analysis of single-dose administration, in which mean glucose levels increased to ≥200 µg and then normalized 23 h after injection [45]. In a previous case study, normalization of glycemic levels was demonstrated in a patient who discontinued pasireotide SC because of lack of response to treatment [44]. In a phase 3 clinical trial of patients with acromegaly who were treated with pasireotide, mean FPG and mean HbA1c levels were reduced to 104 mg/dL (mean value at baseline, 127 mg/dL) and to 6.12 % (mean value at baseline, 6.71 %), respectively, within 3 months of switching from pasireotide LAR to octreotide LAR [28]. In conclusion, hyperglycemia associated with pasireotide is transient and not expected to cause long-term effects if pasireotide is discontinued.

Conclusions

Pasireotide is a viable medical therapy option for patients with CD or acromegaly but is associated with higher rates of hyperglycemia and diabetes mellitus than other medical therapies. Further research is needed to determine optimal treatment strategies with ADMs to achieve glycemic control in patients with pasireotide-induced hyperglycemia. For example, a multivariate analysis could be performed of baseline FPG and HbA1c levels across clinical studies of pasireotide in CD or acromegaly to further assess the predictability and manageability of pasireotide-induced hyperglycemia. A phase 4 study is currently ongoing that will evaluate the effects of incretin-based therapy compared with insulin on glycemic control at 16 weeks in patients with CD or acromegaly (ClinicalTrials.gov identifier NCT02060383) [46]. Significant progress has been made over the years to better understand the mechanisms by which impaired glucose metabolism in patients is uniquely linked to the disease pathophysiology of CD and acromegaly and how pasireotide modulates insulin secretion and sensitivity. There is growing evidence to demonstrate that proactive management with ADMs can effectively manage hyperglycemia-related AEs associated with pasireotide during the course of treating patients with CD or acromegaly.

Acknowledgments

Assistance with medical writing and editing was provided under the direction of the authors by Paul Cao and Meredith MacPherson, MedThink SciCom, Inc, with support from Novartis Pharmaceuticals Corporation.

Funding

Financial support was provided by Novartis Pharmaceuticals Corporation.

Compliance with ethical standards

Conflict of interest

JMS has received research support from Ipsen Biopharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk, and Pfizer. She is on the speaker’s bureau for Pfizer and Chiasma and has been on an advisory board for Chiasma, Ipsen Biopharmaceuticals, and Corcept.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Pädiatrie

Kombi-Abonnement

Mit e.Med Pädiatrie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Pädiatrie, den Premium-Inhalten der pädiatrischen Fachzeitschriften, inklusive einer gedruckten Pädiatrie-Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Literatur
1.
Zurück zum Zitat Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10CrossRefPubMedPubMedCentral Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674CrossRefPubMed Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674CrossRefPubMed
3.
Zurück zum Zitat Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Endocrine society: acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Endocrine society: acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed
4.
Zurück zum Zitat Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462CrossRefPubMedPubMedCentral Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Signifor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2012) Signifor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2012)
6.
Zurück zum Zitat Signifor LAR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2014) Signifor LAR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2014)
7.
Zurück zum Zitat Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24(1):28–47CrossRefPubMed Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24(1):28–47CrossRefPubMed
8.
Zurück zum Zitat Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716CrossRefPubMed Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716CrossRefPubMed
9.
Zurück zum Zitat Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645–654CrossRefPubMed Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645–654CrossRefPubMed
10.
Zurück zum Zitat Chanson P (2016) Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 103(1):50–58CrossRefPubMed Chanson P (2016) Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 103(1):50–58CrossRefPubMed
11.
Zurück zum Zitat Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) Pasireotide B2305 Study Group: a 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924CrossRefPubMed Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) Pasireotide B2305 Study Group: a 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924CrossRefPubMed
12.
Zurück zum Zitat Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Ravichandran S, Kandra A, Biller BMK (2015) Long-term (5 years) treatment of Cushing’s disease with pasireotide. In: Poster presented at: European congress of endocrinology 2015, May 16–20, Dublin, Ireland Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Ravichandran S, Kandra A, Biller BMK (2015) Long-term (5 years) treatment of Cushing’s disease with pasireotide. In: Poster presented at: European congress of endocrinology 2015, May 16–20, Dublin, Ireland
13.
Zurück zum Zitat Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group: pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791–799PubMedPubMedCentral Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group: pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791–799PubMedPubMedCentral
14.
Zurück zum Zitat Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide C2402 Study Group: pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884CrossRefPubMed Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide C2402 Study Group: pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884CrossRefPubMed
15.
Zurück zum Zitat Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Resendiz K, Hughes G, Hu K, Barkan A (2014) Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17(2):132–140CrossRefPubMed Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Resendiz K, Hughes G, Hu K, Barkan A (2014) Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17(2):132–140CrossRefPubMed
16.
Zurück zum Zitat Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM (2014) Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17(4):320–326CrossRefPubMed Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM (2014) Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17(4):320–326CrossRefPubMed
17.
Zurück zum Zitat Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186CrossRefPubMed Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186CrossRefPubMed
18.
Zurück zum Zitat Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52(5):549–555CrossRef Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52(5):549–555CrossRef
19.
Zurück zum Zitat Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453CrossRefPubMed Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453CrossRefPubMed
20.
Zurück zum Zitat Fagan SP, Azizzadeh A, Moldovan S, Ray MK, Adrian TE, Ding X, Coy DH, Brunicardi FC (1998) Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124(2):254–258 discussion 258–259 CrossRefPubMed Fagan SP, Azizzadeh A, Moldovan S, Ray MK, Adrian TE, Ding X, Coy DH, Brunicardi FC (1998) Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. Surgery 124(2):254–258 discussion 258–259 CrossRefPubMed
21.
Zurück zum Zitat Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plockinger U, Strowski MZ (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92(2):673–680CrossRefPubMed Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plockinger U, Strowski MZ (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92(2):673–680CrossRefPubMed
22.
Zurück zum Zitat Singh V, Grotzinger C, Nowak KW, Zacharias S, Goncz E, Pless G, Sauer IM, Eichhorn I, Pfeiffer-Guglielmi B, Hamprecht B, Wiedenmann B, Plockinger U, Strowski MZ (2007) Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148(8):3887–3899CrossRefPubMed Singh V, Grotzinger C, Nowak KW, Zacharias S, Goncz E, Pless G, Sauer IM, Eichhorn I, Pfeiffer-Guglielmi B, Hamprecht B, Wiedenmann B, Plockinger U, Strowski MZ (2007) Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition. Endocrinology 148(8):3887–3899CrossRefPubMed
23.
Zurück zum Zitat Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48(1):77–85CrossRefPubMed Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48(1):77–85CrossRefPubMed
24.
Zurück zum Zitat Schmid HA, Brue T, Colao A, Gadelha M, Shimon I, Kapur K, D’Amoato L, Pedroncelli AM, Fleseriu M (2014) Effect of pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA). In: Poster presented at: European congress of endocrinology 2014; May 3–7, Wrcoclaw, Poland Schmid HA, Brue T, Colao A, Gadelha M, Shimon I, Kapur K, D’Amoato L, Pedroncelli AM, Fleseriu M (2014) Effect of pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and glucose in patients with inadequately controlled acromegaly: exploratory results from a multicentre, randomized, 24-week study (PAOLA). In: Poster presented at: European congress of endocrinology 2014; May 3–7, Wrcoclaw, Poland
25.
Zurück zum Zitat American Diabetes Association (2015) Glycemic targets. Sec. 6. In: Standards of Medical Care in Diabetes 2015. Diabetes Care. 38(Suppl. 1):S33–S40 American Diabetes Association (2015) Glycemic targets. Sec. 6. In: Standards of Medical Care in Diabetes 2015. Diabetes Care. 38(Suppl. 1):S33–S40
26.
Zurück zum Zitat Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Resendiz K, Ruffin M, Chen Y, Colao A (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18(3):385–394CrossRefPubMed Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Resendiz K, Ruffin M, Chen Y, Colao A (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18(3):385–394CrossRefPubMed
27.
Zurück zum Zitat Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R (2015) Pasireotide B2305 Study Group: pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 18(5):604–612CrossRefPubMed Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R (2015) Pasireotide B2305 Study Group: pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 18(5):604–612CrossRefPubMed
28.
Zurück zum Zitat Freda P, Fleseriu M, van der Lely AJ, Colao A, Sheppard M, Gu F, Shen C-C, Gadelha M, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Bronstein MD (2013) Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, phase III study. In: Poster presented at: European congress of endocrinology 2013; April 27–May 1, Copenhagen, Denmark Freda P, Fleseriu M, van der Lely AJ, Colao A, Sheppard M, Gu F, Shen C-C, Gadelha M, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Bronstein MD (2013) Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, phase III study. In: Poster presented at: European congress of endocrinology 2013; April 27–May 1, Copenhagen, Denmark
29.
Zurück zum Zitat Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRefPubMed Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRefPubMed
30.
Zurück zum Zitat Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH (2014) Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3(2):93–98CrossRefPubMed Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH (2014) Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3(2):93–98CrossRefPubMed
31.
Zurück zum Zitat Shen G, Darstein C, Hermosillo Resendiz K, Hu K (2014) Pharmacokinetic and pharmacodynamic analyses of pasireotide LAR and octreotide LAR: randomized, double-blind, phase III study in patients with medically naïve acromegaly. In: Poster presented at: European congress of endocrinology 2014, May 3–7, Wroclaw, Poland Shen G, Darstein C, Hermosillo Resendiz K, Hu K (2014) Pharmacokinetic and pharmacodynamic analyses of pasireotide LAR and octreotide LAR: randomized, double-blind, phase III study in patients with medically naïve acromegaly. In: Poster presented at: European congress of endocrinology 2014, May 3–7, Wroclaw, Poland
32.
Zurück zum Zitat Shen G, Darstein C, Hermosillo Resendiz K, Hu K (2015) Analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data for efficacy and safety from a randomized phase III study of pasireotide LAR in patients with acromegaly inadequately controlled on first-generation somatostatin analogs (SSA). In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA Shen G, Darstein C, Hermosillo Resendiz K, Hu K (2015) Analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data for efficacy and safety from a randomized phase III study of pasireotide LAR in patients with acromegaly inadequately controlled on first-generation somatostatin analogs (SSA). In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA
33.
Zurück zum Zitat Helseth R, Carlsen SM, Bollerslev J, Svartberg J, Øksnes M, Skeie S, Fougner SL (2016) Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2):298–307CrossRefPubMed Helseth R, Carlsen SM, Bollerslev J, Svartberg J, Øksnes M, Skeie S, Fougner SL (2016) Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2):298–307CrossRefPubMed
34.
Zurück zum Zitat Gadelha M, Brue T, Fleseriu M, Shimon I, Hermosillo Resendiz K, Kandra A, Perdoncelli AM, Colao A (2015) Proactive monitoring and early intervention in the management of pasireotide-induced hyperglycemia: lessons from the phase III, 24-week PAOLA study. In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA Gadelha M, Brue T, Fleseriu M, Shimon I, Hermosillo Resendiz K, Kandra A, Perdoncelli AM, Colao A (2015) Proactive monitoring and early intervention in the management of pasireotide-induced hyperglycemia: lessons from the phase III, 24-week PAOLA study. In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA
35.
Zurück zum Zitat Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103(3):458–465CrossRefPubMed Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 103(3):458–465CrossRefPubMed
36.
Zurück zum Zitat Kim MH, Jee JH, Park S, Lee MS, Kim KW, Lee MK (2014) Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol 220(2):117–128CrossRefPubMed Kim MH, Jee JH, Park S, Lee MS, Kim KW, Lee MK (2014) Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol 220(2):117–128CrossRefPubMed
37.
Zurück zum Zitat Colao A, Gu F, Gadelha MR, van der Lely AJ, Fleseriu M, Passos VQ, Ravichandran S, Chen Y, Bronstein MD (2015) Metformin-based oral antidiabetic therapy is effective at controlling hyperglycemia associated with pasireotide in patients with acromegaly. In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA Colao A, Gu F, Gadelha MR, van der Lely AJ, Fleseriu M, Passos VQ, Ravichandran S, Chen Y, Bronstein MD (2015) Metformin-based oral antidiabetic therapy is effective at controlling hyperglycemia associated with pasireotide in patients with acromegaly. In: Poster presented at: Endocrine society annual meeting 2015; March 5–8, San Diego, CA
38.
Zurück zum Zitat Shimon I, Rot L, Inbar E (2012) Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15(4):608–613CrossRefPubMed Shimon I, Rot L, Inbar E (2012) Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15(4):608–613CrossRefPubMed
39.
Zurück zum Zitat Mercado J, Moloney K, Ludlam WH, Broyles F (2013) Sustained improvements in clinical status and quality of life in a patient with recurrent Cushing’s disease treated with pasireotide. In: Poster presented at: American association of clinical endocrinologists 22nd annual scientific and clinical congress; May 1–5, Phoenix, AZ Mercado J, Moloney K, Ludlam WH, Broyles F (2013) Sustained improvements in clinical status and quality of life in a patient with recurrent Cushing’s disease treated with pasireotide. In: Poster presented at: American association of clinical endocrinologists 22nd annual scientific and clinical congress; May 1–5, Phoenix, AZ
40.
Zurück zum Zitat Mercado J, Moloney K, Ludlam WH, Broyles F (2013) Oral antidiabetic management of hyperglycemia in a patient with Cushing’s disease treated with pasireotide: a case study. In: Poster presented at: American association of clinical endocrinologists 22nd annual scientific and clinical congress; May 1–5, Phoenix, AZ Mercado J, Moloney K, Ludlam WH, Broyles F (2013) Oral antidiabetic management of hyperglycemia in a patient with Cushing’s disease treated with pasireotide: a case study. In: Poster presented at: American association of clinical endocrinologists 22nd annual scientific and clinical congress; May 1–5, Phoenix, AZ
41.
Zurück zum Zitat Broyles F, Ludlam WH, Mayberg M (2014) Successful long-term management of refractory Cushing’s disease with pasireotide: a case report. In: Poster presented at: Endocrine society annual meeting 2014; May 14–18, Las Vegas, NV Broyles F, Ludlam WH, Mayberg M (2014) Successful long-term management of refractory Cushing’s disease with pasireotide: a case report. In: Poster presented at: Endocrine society annual meeting 2014; May 14–18, Las Vegas, NV
42.
Zurück zum Zitat Lu L, Duan L, Jin Z, Lu Z, Gu F (2013) Effective long-term treatment of Cushing’s disease with pasireotide: a case report. Endocr Pract 19(4):e92–e96CrossRefPubMed Lu L, Duan L, Jin Z, Lu Z, Gu F (2013) Effective long-term treatment of Cushing’s disease with pasireotide: a case report. Endocr Pract 19(4):e92–e96CrossRefPubMed
43.
Zurück zum Zitat Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verges B (2013) Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab 39(1):34–41CrossRefPubMed Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verges B (2013) Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab 39(1):34–41CrossRefPubMed
44.
Zurück zum Zitat MacKenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2014) Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary 17(6):519–529CrossRefPubMed MacKenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2014) Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary 17(6):519–529CrossRefPubMed
45.
Zurück zum Zitat Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M (2012) A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 6:71–79CrossRefPubMedPubMedCentral Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M (2012) A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 6:71–79CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Gu F, Ravichandran S, Tseng L, Subramanian A, Chen Y, Schofl C (2015) Management of pasireotide-induced hyperglycemia in patients with Cushing’s disease or acromegaly: study design of a randomized, open-label, phase IV trial. In: Poster presented at: Endocrine society annual meeting 2015, March 5–8, San Diego, CA Gu F, Ravichandran S, Tseng L, Subramanian A, Chen Y, Schofl C (2015) Management of pasireotide-induced hyperglycemia in patients with Cushing’s disease or acromegaly: study design of a randomized, open-label, phase IV trial. In: Poster presented at: Endocrine society annual meeting 2015, March 5–8, San Diego, CA
Metadaten
Titel
Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
verfasst von
Julie M. Silverstein
Publikationsdatum
12.07.2016
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 5/2016
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0734-1

Weitere Artikel der Ausgabe 5/2016

Pituitary 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.